Stockscreener 앱 받기
2.525
0.40%
-0.005
전일 마감가:
$2.53
열려 있는:
$2.55
하루 거래량:
370.85K
Relative Volume:
0.54
시가총액:
$129.37M
수익:
$488.00K
순이익/손실:
$-41.44M
주가수익비율:
-2.8056
EPS:
-0.9
순현금흐름:
$-31.47M
1주 성능:
-11.27%
1개월 성능:
-9.03%
6개월 성능:
-28.81%
1년 성능:
+119.13%
1일 변동 폭
$2.465
$2.59
1주일 범위
$2.465
$2.88
52주 변동 폭
$1.13
$6.42
Cardiff Oncology Inc Stock (CRDF) Company Profile
명칭
Cardiff Oncology Inc
전화
858-952-7570
주소
11055 FLINTKOTE AVENUE, SAN DIEGO, CA
CRDF을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
| CRDF | 2.525 | 129.37M | 488.00K | -41.44M | -31.47M | -0.90 |
| VRTX | 448.50 | 115.43B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 746.23 | 82.04B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 597.88 | 35.30B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 246.48 | 32.04B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 108.11 | 24.89B | 3.30B | -501.07M | 1.03B | 11.54 |
Cardiff Oncology Inc Stock (CRDF) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2022-01-05 | 개시 | William Blair | Outperform |
| 2021-12-08 | 개시 | Robert W. Baird | Outperform |
| 2021-08-09 | 재개 | Maxim Group | Buy |
| 2020-10-22 | 개시 | H.C. Wainwright | Buy |
| 2020-10-08 | 개시 | Piper Sandler | Overweight |
Cardiff Oncology Inc 주식(CRDF)의 최신 뉴스
Cardiff Oncology secures patent for cancer drug combo - Investing.com India
Cardiff Oncology Announces New Patent with Claims for the Use of Onvansertib in Treating KRAS mutated mCRC - GlobeNewswire
CRDFCardiff Oncology, Inc. Latest Stock News & Market Updates - StockTitan
Cardiff Oncology Announces New Patent with Claims for the Use of Onvansertib in Treating KRAS ... - News-Press Now
Cardiff Oncology Secures Patent for Cancer Drug Combo Through 2043 | CRDF Stock News - StockTitan
Cardiff Oncology: Q3 Earnings Snapshot - AOL
HC Wainwright Has Lowered Expectations for Cardiff Oncology (NASDAQ:CRDF) Stock Price - MarketBeat
Cardiff Oncology Third Quarter 2024 Earnings: Beats Expectations - Yahoo Finance
Cardiff Oncology Reports Positive Q3 2024 Results and Clinical Progress - TipRanks
Cardiff Oncology (CRDF) Reports Q3 Loss, Tops Revenue Estimates - MSN
Cardiff Oncology Reports 7.7x Better Results in Phase 2 Cancer Trial, $57.7M Cash Position | CRDF Stock News - StockTitan
Cardiff Oncology, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Cardiff Oncology: Some Data Are In; Here's What You Should Know And Look For Next - Seeking Alpha
Cardiff Oncology, Inc. (NASDAQ:CRDF) Shares Sold by Assenagon Asset Management S.A. - MarketBeat
Cardiff Oncology (FRA:XE7C) Float Percentage Of Total Shares Outstanding : 97.27% (As of Nov. 02, 2024) - GuruFocus.com
Cardiff Oncology, Inc. (NASDAQ:CRDF) Short Interest Up 7.2% in October - MarketBeat
Cardiff Oncology Announces Journal of Clinical Oncology - GlobeNewswire
Cardiff Oncology Announces Journal of Clinical Oncology Publication of Data from Phase 2 Trial in Second-line KRAS Mutant mCRC - StockTitan
Alley Investment Management Company LLC Purchases New Stake in NVIDIA Co. (NASDAQ:NVDA) - Defense World
NA Liquid Biopsy Market 2024 To Witness Amazing Growth By 2032 - openPR
3 US Penny Stocks With Market Caps Over $40M - Simply Wall St
JAK Inhibitors Clinical Trial Pipeline Experiences Momentum: DelveInsight Estimates a Diverse Pipeline Comprising 50+ Companies Working in the Domain - The Malaysian Reserve
KRAS Inhibitors Market Poised to Reach $157.6 Million by 2031, Driven by 5.61% CAGR As Revealed In New Report - WhaTech
Will Cardiff Oncology's Onvansertib Data Boost Its Stock Price? - RTTNews
Metastatic Castration-Resistant Prostate Cancer Clinical Trial Pipeline Appears Robust With 90+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight - The Malaysian Reserve
Cardiff Oncology Inc’s: Contrasting Stock Performances in a Volatile Market - The InvestChronicle
Cardiff Oncology Inc (CRDF) Q2 2024 Earnings Call Highlights: Strategic Trials and Financial ... - Yahoo Finance
Neuroendocrine Tumors Pipeline Therapeutics, Assessment, Companies, Products, Unmet Needs, Market Drivers and Barriers - Barchart
We're Keeping An Eye On Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Rate - Simply Wall St
Its Stock Has Paid Off Big Time For Cardiff Oncology Inc - SETE News
Stock Performance Spotlight: Cardiff Oncology Inc (CRDF) Ends the Day at 2.60, Up by 2.77 - The Dwinnex
CRDF (Cardiff Oncology Inc) has impressive results - US Post News
Cardiff Oncology: Paramount Data Imminent In Huge First-Line mCRC Market - Seeking Alpha
Take off with Cardiff Oncology Inc (CRDF): Get ready for trading - SETE News
Market Insight: Cardiff Oncology Inc (CRDF)’s Notable Drop, Closing at 2.47 - The Dwinnex
How to interpret Cardiff Oncology Inc (CRDF)’s stock chart patterns - US Post News
PLK-1 Inhibitors Market to Register Immense Growth by 2034 | DelveInsight - The Malaysian Reserve
Bristol-Myers Squibb (NYSE:BMY) Shares Bought by Sunbelt Securities Inc. - Defense World
KRAS Inhibitors Market: New Treatments Are Set to Change Cancer Care | DelveInsight - 新浪香港
IGC Pharma, Inc. (NYSEMKT:IGC) Director Buys $199,999.90 in Stock - Defense World
Blair William & Co. IL Raises Stake in Cardiff Oncology, Inc. (NASDAQ:CRDF) - Defense World
Delta Investment Management LLC Cuts Stock Position in JPMorgan Ultra-Short Income ETF (NYSEARCA:JPST) - Defense World
Cardiff City . . . The Doom Loop Club Stuck On Groundhog Day - Dai Sport
Investment Opportunities: Capitalizing on the Global Kras - openPR
Cardiff City need 'long-term strategy' after Erol Bulut exitRob Earnshaw - BBC.com
Tonight's Cardiff City news as 'stunned' club release statement and pundit picks 'fantastic' fit for job - Yahoo News UK
Trading Day Review: Cardiff Oncology Inc (CRDF) Loses Momentum, Closing at 2.58 - The Dwinnex
Cardiff Oncology Inc (CRDF) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.80%
0.42%
자본화:
|
볼륨(24시간):